4.3 Article

LEF1 reduces tumor progression and induces myodifferentiation in a subset of rhabdomyosarcoma

Journal

ONCOTARGET
Volume 8, Issue 2, Pages 3259-3273

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.13887

Keywords

RMS; LEF1/TCF; WNT/beta-catenin signaling

Funding

  1. German Research Foundation DFG [HA 2197/9-1]
  2. German Cancer Aid DKH [111537]
  3. Margarete-von-Wrangell fellowship

Ask authors/readers for more resources

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and show characteristics of skeletal muscle differentiation. The two major RMS subtypes in children are alveolar (ARMS) and embryonal RMS (ERMS). We demonstrate that approximately 50% of ARMS and ERMS overexpress the LEF1/TCF transcription factor LEF1 when compared to normal skeletal muscle and that LEF1 can restrain aggressiveness especially of ARMS cells. LEF1 knockdown experiments in cell lines reveal that depending on the cellular context, LEF1 can induce pro-apoptotic signals. LEF1 can also suppress proliferation, migration and invasiveness of RMS cells both in vitro and in vivo. Furthermore, LEF1 can induce myodifferentiation of the tumor cells. This may involve regulation of other LEF1/TCF factors i.e. TCF1, whereas beta-catenin activity plays a subordinate role. Together these data suggest that LEF1 rather has tumor suppressive functions and attenuates aggressiveness in a subset of RMS.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available